Skip to content
  • News
  • Compare
  • Capital
variis
  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Events
  • Funds
  • Press
variis

Longevity intelligence for Singapore and Australia. Sourced and evidence-graded.

Directories

  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Funds
  • Events

Read

  • Archive
  • Capital
  • Compare
  • Glossary

Markets

  • Singapore
  • Australia

variis

  • About
  • Editorial standards
  • AI transparency
  • Corrections
  • Press

Legal

  • Medical disclaimer
  • Privacy policy
  • Terms of service

AI-assisted reporting, human-reviewed. Every claim sourced and graded. Not medical advice.

© 2026 variis · Singapore · Australia

  1. Home
  2. Companies
  3. Genetic Signatures Limited

Company

Genetic Signatures Limited

ASX:GSS

Molecular diagnostics company built on its proprietary 3base sample-chemistry platform, which converts non-methylated cytosines before amplification to reduce sequence complexity and allow highly multiplexed real-time PCR. It sells EasyScreen kits and the GS1 automated workflow to clinical laboratories for gastrointestinal (bacterial, viral, parasitic), respiratory, and vaccine-preventable pathogen detection, with customers in Australia, the UK, and the US. Longevity relevance is peripheral and indirect: the exposure is infectious disease testing infrastructure, not ageing biology, biological age measurement, or any geroscience intervention. It belongs in the universe on the diagnostics limb and on ASX listing, not on scientific proximity to healthspan. Nothing in its product line targets ageing mechanisms.

At a glance

Listing
ASX:GSS
Category
Diagnostics
Headquarters
Newtown, Sydney, NSW, Australia
Market cap
Approximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only.

Thesis

Why it is in this universe

Category
Diagnostics
Market
Australia
Recent inflection
On 2 July 2026, BCAL Diagnostics acquired a 10.2 percent stake (23,173,644 shares at 6.0 cents, A$1,390,119) in Genetic Signatures, framed as a strategic position in a complementary diagnostics company with existing PCR manufacturing, regulatory clearances, and distribution in Australia, the UK, and the US. The stake was taken against a weak backdrop: H1 FY26 revenue of about A$8.7 million (up 2.4 percent year on year) with the board conceding that US sales of its key commercialised product had fallen short of expectations, and the shares near 52-week lows. Source: Sharecafe, 2 July 2026, corroborated by Kalkine and an Investing.com H1 FY26 earnings call transcript.
Services
None recorded
People tracked
1

Market data

Listing and scale

MetricDetail
ExchangeASX
TickerASX:GSS
Secondary listingNone
Market capApproximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only.
StatusListed and trading
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address
Newtown, Sydney, NSW, Australia
Website
www.geneticsignatures.com
Phone
No public number published
Email
No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

People

Who variis tracks here (1)

variis does not publish portraits of named individuals without a licence to do so.

  • RMDr Rory MelvilleMedical Healthspan AlliancePublished as a general practitioner (GP); FRACGP fellowship stated on his clinic's own team page. Not confirmed against the AHPRA register.MBChB, MRCGP, FRACGP; Diploma in Geriatric Medicine; Certificate course in Healthy Longevity Medicine (as published on his clinic's team page)Registration published, unchecked

Recent inflection

What moved lately

On 2 July 2026, BCAL Diagnostics acquired a 10.2 percent stake (23,173,644 shares at 6.0 cents, A$1,390,119) in Genetic Signatures, framed as a strategic position in a complementary diagnostics company with existing PCR manufacturing, regulatory clearances, and distribution in Australia, the UK, and the US. The stake was taken against a weak backdrop: H1 FY26 revenue of about A$8.7 million (up 2.4 percent year on year) with the board conceding that US sales of its key commercialised product had fallen short of expectations, and the shares near 52-week lows. Source: Sharecafe, 2 July 2026, corroborated by Kalkine and an Investing.com H1 FY26 earnings call transcript.

Common questions

Why does variis track Genetic Signatures Limited?
Molecular diagnostics company built on its proprietary 3base sample-chemistry platform, which converts non-methylated cytosines before amplification to reduce sequence complexity and allow highly multiplexed real-time PCR. It sells EasyScreen kits and the GS1 automated workflow to clinical laboratories for gastrointestinal (bacterial, viral, parasitic), respiratory, and vaccine-preventable pathogen detection, with customers in Australia, the UK, and the US. Longevity relevance is peripheral and indirect: the exposure is infectious disease testing infrastructure, not ageing biology, biological age measurement, or any geroscience intervention. It belongs in the universe on the diagnostics limb and on ASX listing, not on scientific proximity to healthspan. Nothing in its product line targets ageing mechanisms.
Is Genetic Signatures Limited publicly listed?
Yes. It trades as ASX:ASX:GSS. Market capitalisation is in the Approximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only. range, recorded as a dated snapshot rather than a live quote.
Where is Genetic Signatures Limited based?
Newtown, Sydney, NSW, Australia
Is Genetic Signatures Limited still trading?
Genetic Signatures Limited is recorded as actively trading.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

  1. Genetic Signatures: company site, 3base platform and EasyScreen product lines, registered office 7 Eliza Street, Newtown NSW 2042 · Genetic Signatures Limited
  2. BCAL Diagnostics Acquires Strategic Stake in Genetic Signatures · Sharecafe
  3. BCAL Diagnostics Acquires 10.2% Stake in Genetic Signatures for $1.39 Million · Kalkine
  4. Earnings call transcript: Genetic Signatures reports H1 FY26 results amid U.S. growth focus · Investing.com
  5. ASX Health Stocks: Genetic Signatures gets FDA approval for EasyScreen Gastrointestinal Parasite Detection Kit and GS1 workflow · Stockhead

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.